Article

TCR-engineered T-cells directed against Ropporin-1 constitute a safe and effective treatment for triple-negative breast cancer in near-clinical models

2024-01-11

Abstract excerpt

Triple-negative breast cancer (TNBC) shows an urgent need for new therapies. We discovered Ropporin-1 (ROPN1) as a target to treat TNBC with T-cells. ROPN1 showed high and homogenous expression in 90% of primary and metastatic TNBC but not in healthy tissues. HLA-A2-binding peptides were detected via immunopeptidomics and predictions and used to retrieve T-cell receptors (TCRs) from naïve repertoires. Following ge...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4eda5e96-c9ae-5e96-a695-f421480cb9f5
DOI: 10.1101/2024.01.10.574978

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

TCR-engineered T-cells directed against Ropporin-1 constitute a safe and effective treatment for triple-negative breast cancer in near-clinical modelsDOI 10.1101/2024.01.10.574978Read

TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast CancerSemantic proximity Read

Targeting of intracellular oncoproteins with peptide-centric CARs.Semantic proximity Read

RIPTACs: A groundbreaking approach to drug discoverySemantic proximity Read

Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast CancerSemantic proximity Read

Phenotypes and cytokines of NK cells in triple-negative breast cancer resistant to checkpoint blockade immunotherapySemantic proximity Read

LRP-1 promotes tumor progression of triple negative breast cancers by coordinating extracellular matrix remodeling and immune cell infiltrationSemantic proximity Read

IFNγ Modulates the Immunopeptidome of Triple Negative Breast Cancer Cells by Enhancing and Diversifying Antigen Processing and PresentationSemantic proximity Read

Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers.Semantic proximity Read

Mesothelin- and nucleolin-specific T cells from combined short peptides effectively kill triple-negative breast cancer cellsSemantic proximity Read

Selection of Novel Peptides Homing the 4T1 CELL Line: Exploring Alternative Targets for Triple Negative Breast CancerSemantic proximity Read

Advancement in precision diagnosis and therapeutic for triple-negative breast cancer: Harnessing diagnostic potential of CRISPR-cas & engineered CAR T-cells mediated therapeuticsSemantic proximity Read

Antigen/HLA-agnostic strategies for Characterizing Tumor-responsive T cell receptors in PDAC patients via single-cell sequencing and autologous organoid applicationSemantic proximity Read